Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Prepaid Assets (2020 - 2025)

Historic Prepaid Assets for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to $3.6 million.

  • Oncology Institute's Prepaid Assets fell 1190.53% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 1190.53%. This contributed to the annual value of $4.0 million for FY2024, which is 49.39% down from last year.
  • As of Q3 2025, Oncology Institute's Prepaid Assets stood at $3.6 million, which was down 1190.53% from $2.8 million recorded in Q2 2025.
  • Oncology Institute's 5-year Prepaid Assets high stood at $11.2 million for Q4 2021, and its period low was $82245.0 during Q3 2021.
  • Moreover, its 5-year median value for Prepaid Assets was $4.2 million (2023), whereas its average is $5.1 million.
  • Per our database at Business Quant, Oncology Institute's Prepaid Assets plummeted by 5932.23% in 2021 and then surged by 920755.67% in 2022.
  • Over the past 5 years, Oncology Institute's Prepaid Assets (Quarter) stood at $11.2 million in 2021, then plummeted by 38.23% to $6.9 million in 2022, then plummeted by 41.47% to $4.0 million in 2023, then dropped by 0.49% to $4.0 million in 2024, then dropped by 11.29% to $3.6 million in 2025.
  • Its Prepaid Assets stands at $3.6 million for Q3 2025, versus $2.8 million for Q2 2025 and $5.1 million for Q1 2025.